Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Louisiana IVIG Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross and Blue Shield of LouisianaPolicy 00170

    Immune Globulin Therapy

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy 00170 alerts

    Get alerted when Policy 00170 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for intravenous immune globulin (IVIG) and subcutaneous immune globulin (SCIG), including covered indications, clinical criteria, product step therapy, continuation requirements, and investigational uses. It applies to products administered or underwritten by Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc., subject to member contract benefits.

    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyImmune Globulin Therapy
    Policy CodePolicy 00170
    Change TypeModified
    Effective DateJanuary 1, 2027
    Last ReviewOct 1, 2026
    Next Review DateOctober 1, 2027
    Key ActionSubmit prior authorization requests for IVIG and SCIG with the applicable indication criteria and required product trials or a supported exception.
    SourceLink
    POLICY UPDATE CHANGES

    Severe anemia due to parvovirus B19 was added as an eligible hematologic indication for intravenous immune globulin therapy.

    Kawasaki disease was deleted as an infectious-disease indication for intravenous immune globulin therapy.

    Crohn disease, opsoclonus-myoclonus, birdshot retinopathy, epidermolysis bullosa acquisita, necrotizing fasciitis, and polyradiculoneuropathy other than CIDP were identified as investigational applications of intravenous immune globulin.

    Prevention of sepsis in certain young populations was added as an indication tracked by the policy.

    Hemolytic disease of the fetus and newborn, also called erythroblastosis fetalis, was added as an indication.

    The coding section was revised to add ICD-10 diagnosis codes, remove ICD-9 procedure codes, and add HCPCS codes.

    The policy removed prevention of infection in preterm and/or low-birth-weight neonates.

    Alyglo and Yimmugo were added to the immune globulin therapy policy.

    Carimune, Gamastan S/D, and Polygam S/D were removed from the policy as discontinued products.

    The structure of the covered indications was updated.

    A Primary Immunodeficiency Syndromes section was added to the Policy Guidelines.

    A definition for severe refractory Myasthenia Gravis was added.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    43Document pages
    2Administration modalities
    2Core coverage prerequisites
    2Preferred products required for selected products
    7Investigational applications identified

    Coverage Criteria

    IVIG Initial Therapy

    IVIG may be eligible for coverage when ALL applicable criteria below are met.

    ALL of the following

    • A covered indication

      • Primary immunodeficiency, including congenital agammaglobulinemia, hypogammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia (Bruton's), X-linked hyperimmunoglobulinemia M syndrome, severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), ataxia telangiectasia, or IgG subclass deficiency.
      • Chronic lymphocytic leukemia (CLL) with IgG less than 400 mg/dL and persistent bacterial infections.
      • Prior to solid-organ transplant for patients at high risk of antibody-mediated rejection, including highly sensitized patients and those receiving an ABO-incompatible organ.
      • Following solid-organ transplant for treatment of antibody-mediated rejection (AMR).
      • Hematopoietic cell transplantation in patients with IgG less than 400 mg/dL.
      • HIV-infected children with IgG less than 400 mg/dL to prevent opportunistic infections.
      • Toxic shock syndrome.
      • Severe anemia due to human parvovirus B19.
      • Acute, severe idiopathic thrombocytopenic purpura (ITP).
      • Chronic ITP of at least 6 months' duration with symptoms and persistent thrombocytopenia despite corticosteroids and splenectomy: platelets less than 20,000 per microliter in adults or less than 30,000 per microliter in children.
      • Warm-antibody autoimmune hemolytic anemia refractory to corticosteroids and immunosuppressive agents.
      • Antiphospholipid syndrome.
      • Wegener granulomatosis.
      • Severe refractory myasthenia gravis (MGFA class IV) with chronic debilitating disease despite cholinesterase inhibitors, or complications from or failure of corticosteroids and/or azathioprine.
      • Myasthenic exacerbation with acute respiratory muscle weakness when plasma exchange is contraindicated.
      • Guillain-Barré syndrome (GBS).
      • Chronic inflammatory demyelinating polyneuropathy (CIDP) with progressive symptoms for at least 2 months.
      • Multifocal motor neuropathy (MMN).
      • Eaton-Lambert myasthenic syndrome after failure to respond to anticholinesterase medications and/or corticosteroids.
      • Neuromyelitis optica when steroids or plasma exchange are contraindicated or ineffective.
      • Dermatomyositis or polymyositis refractory to corticosteroids, in combination with other immunosuppressive agents.
      • Severe progressive autoimmune mucocutaneous blistering disease despite conventional agents, including pemphigus, pemphigoid, pemphigus vulgaris, or pemphigus foliaceus.
      • Neonatal alloimmune thrombocytopenia.
      • Hemolytic disease of the fetus and newborn (erythroblastosis fetalis).
      • Stiff person syndrome not controlled by other therapies.
      • Stevens-Johnson syndrome or toxic epidermal necrolysis.
    • For primary immunodeficiency, ALL of the following additional criteria

      • Laboratory evidence of immunoglobulin deficiency.
      • Documented inability to mount an adequate immunologic response to inciting antigens.
      • Persistent and severe infections despite treatment with prophylactic antibiotics.
    • Product-specific requirements, when applicable

      • For Flebogamma, Gammagard S/D, Gammaplex, Panzyga, Alyglo, Yimmugo, or Qivigy: the patient has tried and failed two of Gammagard Liquid, Gamunex-C, Gammaked, Octagam, Privigen, or Bivigam, due to intolerance or inadequate response, unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.
      • For Asceniv: the patient has tried and failed all of Flebogamma, Gammagard, Gamunex-C, Gammaplex, Gammaked, Octagam, Privigen, Bivigam, Panzyga, Alyglo, Yimmugo, and Qivigy, due to intolerance or inadequate response.

    IVIG Reauthorization

    Reauthorization requires ALL of the following:

    ALL of the following

    • The patient received an initial authorization.
    • The patient experienced and maintained a clinically meaningful response to the requested medication.

    SCIG Initial Therapy

    SCIG may be eligible for coverage when ALL applicable criteria below are met.

    ALL of the following

    • A listed indication

      • Primary immunodeficiency, including congenital agammaglobulinemia, hypogammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), or X-linked agammaglobulinemia (XLA).
      • Chronic inflammatory demyelinating polyneuropathy (CIDP).
    • For primary immunodeficiency, ALL of the following requirements

      • Laboratory evidence of immunoglobulin deficiency.
      • Documented inability to mount an adequate immunologic response to inciting antigens.

    SCIG Reauthorization

    SCIG reauthorization requires documentation of a positive response to therapy.

    ALL of the following

    • The patient received an initial authorization.
    • The patient experienced and maintained a clinically meaningful or positive response to SCIG therapy.

    PANDAS

    PANDAS with immune-modulating therapies should not be treated outside of the research setting.

    ALL of the following

    • Treatment is provided within a research setting.

    Coverage is not available for investigational medical treatments or procedures, drugs, devices, or biological products. Other applications of IVIG therapy are considered investigational, including but not limited to chronic progressive multiple sclerosis; refractory rheumatoid arthritis and other connective-tissue diseases, including systemic lupus erythematosus; recurrent spontaneous abortion; inclusion-body myositis; immune optic neuritis; myasthenia gravis in patients responsive to immunosuppressive treatment; vasculitides other than Kawasaki disease; thrombotic thrombocytopenic purpura; hemolytic uremic syndrome; paraneoplastic syndromes other than Eaton-Lambert myasthenic syndrome; paraproteinemic neuropathy; epilepsy; chronic sinusitis; asthma; chronic fatigue syndrome; acute myocarditis; refractory recurrent pericarditis; aplastic anemia; Diamond-Blackfan anemia; red cell aplasia; acquired factor VIII inhibitors; hemophagocytic syndrome; acute lymphoblastic leukemia; multiple myeloma; immune-mediated neutropenia; nonimmune thrombocytopenia; cystic fibrosis; recurrent otitis media; diabetes mellitus; Behcet's syndrome; adrenoleukodystrophy; uveitis; recent-onset dilated cardiomyopathy; Fisher syndrome; autism spectrum disorder; complex regional pain syndrome; Alzheimer's disease; postpolio syndrome; neonatal sepsis; adult sepsis; and other nonlisted applications.

    This policy focuses on nonspecific pooled IVIG preparations and does not address intramuscular immune globulin (IMIG) depot injections or other preparations used for passive immunization to specific antigens, such as respiratory syncytial virus, cytomegalovirus, or hepatitis B.

    PANDAS treatment with immune-modulating therapies is not covered outside of the research setting.

    Kawasaki disease was deleted from the covered infectious-disease indications for IVIG therapy.

    Kawasaki disease is no longer listed as an indication eligible for IVIG coverage.

    IVIG is not medically necessary when the patient-selection criteria are not met.

    IVIG reauthorization is not medically necessary when there is no documentation of a positive response to IVIG.

    SCIG is not medically necessary when the patient-selection criteria are not met.

    SCIG reauthorization is not medically necessary when there is no documentation of a positive response to therapy.

    Investigational IVIG applications include Crohn disease, opsoclonus-myoclonus, birdshot retinopathy, epidermolysis bullosa acquisita, necrotizing fasciitis, and polyradiculoneuropathy other than CIDP.

    Initial Authorization Criteria

    IVIG Initial Authorization

    Covered when the patient has a listed IVIG indication, meets the applicable indication-specific clinical criteria, and satisfies required product sequencing.

    IVIG initial authorization

    • Covered indication: Primary immunodeficiency; CLL with IgG less than 400 mg/dL and persistent bacterial infections; qualifying transplant or hematopoietic cell transplantation use; HIV-infected children with IgG less than 400 mg/dL; toxic shock syndrome; severe anemia due to parvovirus B19; ITP; warm antibody autoimmune hemolytic anemia; antiphospholipid syndrome; Wegener granulomatosis; severe refractory myasthenia gravis; myasthenic exacerbation with contraindication to plasma exchange; GBS; CIDP; MMN; Eaton-Lambert myasthenic syndrome; neuromyelitis optica; refractory dermatomyositis or polymyositis; Kawasaki syndrome; severe refractory autoimmune mucocutaneous blistering disease; neonatal alloimmune thrombocytopenia; hemolytic disease of the fetus and newborn; stiff person syndrome; or SJS/TEN.
    • Product-specific step therapy: For Flebogamma, Gammagard S/D, Gammaplex, Panzyga, Alyglo, Yimmugo, or Qivigy, the patient has tried and failed two of Gammagard Liquid, Gamunex-C, Gammaked, Octagam, Privigen, or Bivigam.

      An exception applies when clinical evidence or patient history indicates the preferred products would be ineffective or cause an adverse reaction.

    Continuation and Reauthorization

    Preferred Product Sequencing

    Products requiring step therapyRequired trialException
    Flebogamma; Gammagard S/D; Gammaplex; Panzyga; Alyglo; Yimmugo; or QivigyTry and fail (intolerance or inadequate response) two of: Gammagard Liquid, Gamunex-C, Gammaked, Octagam, Privigen, or BivigamMay be waived when clinical evidence or patient history suggests the products would be ineffective or cause an adverse reaction
    Requested productRequired trialException
    AscenivTry and fail (intolerance or inadequate response) all of: Flebogamma, Gammagard, Gamunex-C, Gammaplex, Gammaked, Octagam, Privigen, Bivigam, Panzyga, Alyglo, Yimmugo, and QivigyNo exception stated
    Requested productRequired trialException
    HyqviaTry and fail (intolerance or inadequate response) two of: Gammagard Liquid, Hizentra, Gamunex-C, Gammaked, Cuvitru, Cutaquig, or XembifyMay be waived when clinical evidence or patient history suggests the products would be ineffective or cause an adverse reaction

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial Authorization Required

    Obtain prior authorization before initiating IVIG or SCIG. The request must identify a covered indication and satisfy the applicable clinical and product-selection criteria.

    • IVIG coverage is limited to the policy-listed indications.
    • SCIG coverage is limited to PID and CIDP indications listed in the SCIG criteria.
    Prior Authorization

    Reauthorization Requires Documented Response

    Reauthorization requires a prior initial authorization and documentation that the patient has received and maintained a clinically meaningful response to the requested medication.

    • Applies to both IVIG and SCIG requests.
    • The record must support continued benefit, not merely ongoing treatment.

    Immune Globulin Therapy Overview

    Immune globulin therapy provides pooled immunoglobulin for antibody replacement in inherited or acquired immunodeficiencies and has also been investigated for immunomodulatory treatment of diseases with an autoimmune basis. This policy addresses outpatient use of both IVIG and SCIG, focusing on nonspecific pooled preparations. IVIG is derived from pooled plasma and contains antibodies against more than 10 million antigens; coverage is addressed for selected immunodeficiency, infectious, autoimmune, inflammatory, alloimmune, transplant, neurologic, and other conditions.

    Clinical Definitions

    MGFA Class IV
    Class IVSevere weakness affecting muscles other than ocular muscles.
    Class IVaWeakness predominantly affects limb or axial muscles, with possible lesser oropharyngeal involvement.
    Class IVbWeakness predominantly affects oropharyngeal or respiratory muscles, with possible lesser or equal limb or axial involvement.
    Primary immunodeficiency treatment criteria
    DeficiencyLaboratory evidence of immunoglobulin deficiency is required.
    Immune responseThe patient must have documented inability to mount an adequate immunologic response to inciting antigens.
    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyImmune Globulin Therapy
    Policy CodePolicy 00170
    Change TypeModified
    Effective DateJanuary 1, 2027
    Last ReviewOct 1, 2026
    Next Review DateOctober 1, 2027
    Key ActionSubmit prior authorization requests for IVIG and SCIG with the applicable indication criteria and required product trials or a supported exception.
    SourceLink
    On This Page
    Coverage CriteriaInitial Authorization CriteriaContinuation and ReauthorizationPreferred Product SequencingAuthorization, Documentation, and Denial RisksImmune Globulin Therapy OverviewClinical Definitions
  1. Persistent and severe infections despite treatment with prophylactic antibiotics.
  2. Product-specific requirement, when applicable

    • For Hyqvia: the patient has tried and failed two of Gammagard Liquid, Hizentra, Gamunex-C, Gammaked, Cuvitru, Cutaquig, or Xembify, due to intolerance or inadequate response, unless clinical evidence or patient history suggests those products will be ineffective or cause an adverse reaction.
    • The request is not for Hyqvia.
  3. Product-specific step therapy: For Asceniv, the patient has tried and failed Flebogamma, Gammagard, Gamunex-C, Gammaplex, Gammaked, Octagam, Privigen, Bivigam, Panzyga, Alyglo, Yimmugo, and Qivigy.
  4. SCIG Initial Authorization

    Covered when the request is for a listed SCIG indication and applicable primary immunodeficiency criteria are met.

    SCIG initial authorization

    • Listed indication: Primary immunodeficiency, including congenital agammaglobulinemia, hypogammaglobulinemia, common variable immunodeficiency, severe combined immunodeficiency, Wiskott-Aldrich syndrome, or X-linked agammaglobulinemia; or CIDP.
    • PID criteria when applicable: For primary immunodeficiency, laboratory evidence of immunoglobulin deficiency, documented inability to mount an adequate immunologic response to inciting antigens, and persistent and severe infections despite treatment with prophylactic antibiotics are documented.
    • Hyqvia sequencing when applicable: For Hyqvia, the patient has tried and failed two of Gammagard Liquid, Hizentra, Gamunex-C, Gammaked, Cuvitru, Cutaquig, or Xembify.

      An exception applies when clinical evidence or patient history indicates the products would be ineffective or cause an adverse reaction.

    SCIG PID Initial Authorization

    SCIG requests for primary immunodeficiency require all of the following clinical evidence.

    Initial SCIG therapy for PID

    • Immunoglobulin deficiency: Laboratory evidence of immunoglobulin deficiency.
    • Impaired immune response: Documented inability to mount an adequate immunologic response to inciting antigens.
    • Persistent severe infections: Persistent and severe infections despite treatment with prophylactic antibiotics.
    Prior Authorization

    SCIG PID Authorization Criteria

    For SCIG requests for PID, document all required criteria: laboratory evidence of immunoglobulin deficiency, inability to mount an adequate immunologic response to inciting antigens, and persistent severe infections despite prophylactic antibiotics.

    • All three criteria are required.
    • The criteria clarify the operational requirements for SCIG PID requests.
    Step Therapy

    Non-Preferred IVIG Products Require Step Therapy

    Requests for listed non-preferred IVIG products require documented trial and failure because of intolerance or inadequate response to two preferred products, unless clinical evidence or patient history indicates the alternatives would be ineffective or cause an adverse reaction.

    • Non-preferred products: Flebogamma, Gammagard S/D, Gammaplex, Panzyga, Alyglo, Yimmugo, and Qivigy.
    • Preferred alternatives include Gammagard Liquid, Gamunex-C, Gammaked, Octagam, Privigen, and Bivigam.
    Step Therapy

    Asceniv Product Sequencing

    For Asceniv, document trials and failure due to intolerance or inadequate response to every specified alternative, unless clinical evidence or patient history supports why an alternative would be ineffective or unsafe.

    • Required alternatives: Flebogamma, Gammagard, Gamunex-C, Gammaplex, Gammaked, Octagam, Privigen, Bivigam, Panzyga, Alyglo, Yimmugo, and Qivigy.
    Step Therapy

    Hyqvia Product Sequencing

    For Hyqvia, document trials and failure due to intolerance or inadequate response to two specified SCIG alternatives, unless clinical evidence or patient history indicates those products would be ineffective or cause an adverse reaction.

    • Alternatives: Gammagard Liquid, Hizentra, Gamunex-C, Gammaked, Cuvitru, Cutaquig, and Xembify.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Denial Risk

    Unmet Criteria or Investigational Use

    Expect denial when patient-selection criteria are not met or when the requested use is investigational. SCIG is investigational for indications not listed in its patient-selection criteria.

    • Unmet IVIG or SCIG selection criteria may be considered not medically necessary.
    • Investigational uses are not covered, including uses outside the applicable listed indications.

    Unsupported block type: denial_risk

    Denial Risk

    Required Product Step Therapy Not Completed

    A request may be denied when required preferred-product trials have not been completed and no documented exception applies.

    • For applicable non-preferred IVIG products, document failure of two preferred products.
    • For Asceniv, document failure of all specified alternatives.
    • For Hyqvia, document failure of two specified SCIG alternatives.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Investigational IVIG Applications

    The policy identifies several IVIG applications as investigational and not covered. Requests for these uses should be expected to deny unless the policy is revised or another applicable benefit governs.

    • Examples include Crohn disease, opsoclonus-myoclonus, birdshot retinopathy, epidermolysis bullosa acquisita, necrotizing fasciitis, and polyradiculoneuropathy other than CIDP.
    • Other listed investigational uses include chronic progressive MS, recurrent spontaneous abortion, inclusion-body myositis, autism spectrum disorder, chronic fatigue syndrome, and postpolio syndrome.
    Denial Risk

    Kawasaki Disease Coverage Status

    Kawasaki disease was identified in policy history as deleted from the infectious-disease indications for IVIG coverage. Verify the current benefit and policy language before relying on this indication.

    • The revision history records deletion of Kawasaki disease as an infectious-disease indication.
    • Do not assume historical indication status establishes current coverage.
    Infections
    Persistent and severe infections must continue despite treatment with prophylactic antibiotics.
    Laboratory evidence of immunoglobulin deficiency
    AgammaglobulinemiaTotal IgG less than 200 mg/dL.
    Persistent hypogammaglobulinemiaTotal IgG less than 400 mg/dL, or at least 2 standard deviations below normal, on at least 2 occasions.
    B lymphocytesAbsence of B lymphocytes may provide laboratory evidence of immunoglobulin deficiency.
    Inadequate antibody response
    Antibody responseAn adequate response requires an appropriate rise in antibody titer after antigen provocation.
    Polysaccharide antigenInadequate response may be shown by lack of an appropriate titer rise after provocation with a polysaccharide antigen.
    Protein antigenInadequate response may also be shown by lack of an appropriate titer rise after provocation with a protein antigen.
    MGFA clinical classification
    Class IAny ocular muscle weakness; all other muscle strength is normal.
    Classes II–IIIMild or moderate weakness affects muscles other than ocular muscles, with predominant limb/axial or oropharyngeal/respiratory involvement.
    Class IVSevere weakness affects muscles other than ocular muscles, predominantly involving limb/axial or oropharyngeal/respiratory muscles.
    Class VIntubation, with or without mechanical ventilation, except during routine postoperative management.
    Quantitative Myasthenia Gravis Score
    Ocular manifestationsDiplopia on lateral gaze and ptosis during upward gaze are graded from none to severe.
    Bulbar manifestationsFacial strength, swallowing 4 ounces of water, and speech after counting from 1 to 50 are assessed.
    EnduranceRight and left arm and leg endurance are measured in seconds in specified positions.
    Respiratory and strength domainsForced vital capacity, hand grip, and head lift are included in the score.
    Severity gradingManifestations are graded from none to mild, moderate, or severe.
    Idiopathic inflammatory myopathies
    Disease typeIdiopathic inflammatory myopathies are autoimmune muscle disorders.
    Weakness patternPolymyositis and dermatomyositis involve proximal muscles, including the hips and thighs, upper arms, and neck.
    DermatomyositisDermatomyositis is associated with characteristic skin manifestations.
    Inclusion body myositisInclusion body myositis most affects the wrists, fingers, and front of the thigh.
    Kawasaki disease
    Disease typeKawasaki disease is a vasculitis that primarily affects children.
    Clinical courseIt is characterized by fever and acute inflammation, lasting an average of 12 days without therapy.
    Coronary complicationsIt may cause coronary artery aneurysms, coronary occlusion, cardiac ischemia, significant morbidity, and death.
    Myasthenia gravis
    Disorder typeMyasthenia gravis is an autoimmune disorder of the neuromuscular junction.
    TargetAntibodies form against postsynaptic acetylcholine receptors of skeletal muscles.
    Weakness patternMuscle strength progressively decreases with repeated use and recovers after rest.
    Guillain-Barré syndrome
    Disease groupGuillain-Barré syndrome comprises acute immune-mediated peripheral polyneuropathies.
    OnsetMuscle weakness develops rapidly.
    MechanismThe immune system damages the peripheral nervous system.
    Chronic inflammatory demyelinating polyneuropathy
    Disease typeCIDP is an acquired neurologic disorder.
    Clinical featuresIt causes progressive weakness and impaired sensory function in the arms and legs.
    Underlying damageThe disorder results from damage to the myelin sheath of peripheral nerves.
    Multifocal motor neuropathy
    Disease typeMultifocal motor neuropathy is a rare neuropathy.
    Weakness patternIt causes progressive, asymmetric weakness and atrophy.
    Sensory findingsSensory abnormalities are absent.
    Eaton-Lambert myasthenic syndrome
    Disease typeEaton-Lambert myasthenic syndrome is an autoimmune disease involving the neuromuscular junction.
    AntibodiesAntibodies are directed against the neuromuscular junction.
    Clinical featuresLower-extremity weakness, autonomic dysfunction, and extraocular muscle impairment may occur.
    AssociationIt is most commonly associated with small-cell lung cancer as a paraneoplastic syndrome.
    Stiff person syndrome
    Disease typeStiff person syndrome is a rare acquired neurologic disorder.
    Muscle findingsProgressive axial muscle stiffness, rigidity, and spasms are characteristic.
    Functional impactThe condition can severely impair ambulation and routine daily activities.
    Neuromyelitis optica
    Disease typeNeuromyelitis optica is an inflammatory disorder of the central nervous system.
    PathologyIt causes severe immune-mediated demyelination and axonal damage.
    Primary sitesThe optic nerves and spinal cord are predominantly affected.
    Neuromyelitis optica
    Central nervous system diseaseNeuromyelitis optica is an inflammatory central nervous system disorder.
    Immune-mediated injurySevere immune-mediated demyelination and axonal damage occur.
    Predominant involvementThe optic nerves and spinal cord are predominantly affected.
    Idiopathic thrombocytopenic purpura
    Disease typeIdiopathic thrombocytopenic purpura is an acquired thrombocytopenia.
    MechanismAutoantibodies target platelet antigens.
    TerminologyIt is also called primary immune thrombocytopenia.
    Neonatal alloimmune thrombocytopenia
    ConditionNeonatal alloimmune thrombocytopenia causes fetal or neonatal thrombocytopenia.
    MechanismA maternal antibody directed against a paternal platelet antigen crosses the placenta.
    ComplicationIntracranial hemorrhage occurs in 10% to 30% of affected neonates.
    Acute antibody-mediated rejection
    Injury typeAcute antibody-mediated rejection is antibody-mediated graft injury after transplantation.
    AntibodiesIt is associated with donor-specific or other allo-antibodies.
    Risk assessmentRisk may be assessed with a panel reactive antibody screen; a PRA greater than 20% indicates sensitization.
    Acute antibody-mediated rejection
    Transplant processAcute antibody-mediated rejection is a transplant rejection process.
    Associated antibodiesThe process is associated with anti-human leukocyte antigen antibodies.
    Evidence qualityEvidence supporting IVIG treatment is very low quality according to GRADE criteria.
    Preterm and low birth weight infants
    Preterm infantAn infant born before 37 weeks of gestational age.
    Low birth weightA birth weight less than 2500 g.
    Clinical contextThese infants are prone to infection because of an immature immune system and increased exposure to nosocomial pathogens.
    Relapsing-remitting multiple sclerosis
    Disease typeRelapsing-remitting multiple sclerosis is an immune-mediated inflammatory disease of the central nervous system.
    PathologyIt attacks and destroys myelinated axons.
    Clinical patternSymptomatic episodes occur months or years apart and affect different anatomic locations.
    Systemic lupus erythematosus
    Disease typeSystemic lupus erythematosus is a chronic inflammatory disease with a relapsing and remitting course.
    AutoantibodiesIt is characterized by an autoantibody response to nuclear and cytoplasmic antigens.
    Organ involvementIt can affect any organ system, particularly the skin, joints, kidneys, blood cells, and nervous system.
    Crohn disease
    Disease typeCrohn disease is an inflammatory condition of unknown etiology.
    Anatomic rangeIt can affect any portion of the gastrointestinal tract, from the mouth to the perianal area.
    Clinical presentationIt has a wide spectrum of clinical presentations.
    Hemophagocytic lymphohistiocytosis
    SyndromeHemophagocytic lymphohistiocytosis is an uncommon, potentially fatal syndrome.
    MechanismIt results from excessive immune activation caused by overactive histiocytes and lymphocytes.
    OriginThe syndrome may be inherited or acquired.
    Recurrent spontaneous abortion
    DefinitionRecurrent spontaneous abortion means three or more pregnancies ending in spontaneous abortion.
    Gestational timingThe losses occur before approximately 16 to 20 weeks of gestational age.
    Associated findingsPatients frequently have immunologic abnormalities, particularly antiphospholipid antibodies.
    PANDAS
    PopulationPANDAS describes a subset of children.
    SymptomsObsessive-compulsive disorder or tic symptoms are exacerbated by group A streptococcal infection.
    DiagnosisDiagnosis requires expert consultation.
    Complex regional pain syndrome
    Disorder typeComplex regional pain syndrome is a disorder of the extremities.
    PainRegional pain is disproportionate in time or degree to the usual course of a known trauma or other lesion.
    Clinical settingThe condition may follow trauma or another lesion.
    Alzheimer disease
    Cognitive outcomesTrials assessed cognition using the Alzheimer Disease Assessment Scale and other cognitive measures.
    Functional outcomesTrials assessed function using the Alzheimer Disease Cooperative Study-Activities of Daily Living Inventory and functional scales.
    Imaging outcomesBrain atrophy was assessed by annualized change in ventricular volume measured by MRI.
    Amyloid outcomesA trial assessed the area under the curve of plasma amyloid β1-40.
    Overall trial findingThe cited randomized trials did not demonstrate significant overall benefit from IVIG.
    Paraproteinemic neuropathy
    DefinitionParaproteinemic neuropathy is a heterogeneous group of neuropathies associated with excess immunoglobulins.
    Source of immunoglobulinsThe immunoglobulins are produced in excess by an abnormal clonal proliferation of B lymphocytes or plasma cells.
    Mechanisms of nerve injuryDisease may result from antibody interaction with peripheral nerve antigens or deposition of immunoglobulin or amyloid.
    Refractory recurrent pericarditis
    DefinitionRefractory recurrent pericarditis is recurrent pericarditis that does not respond to conventional anti-inflammatory treatment.
    Conventional treatmentsTreatments include aspirin, nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine.
    Clinical evidenceThe summarized evidence included 30 patients from 4 case series and 13 case reports.
    Noninfectious uveitis
    DefinitionNoninfectious uveitis is inflammation of the eye resulting from noninfectious causes.
    Possible causesCauses include eye trauma, anomalous immune processes, or unknown etiology.
    Evidence contextTwo small case series provided insufficient evidence to draw conclusions about efficacy.
    Hemolytic disease of the fetus and newborn
    Primary termHemolytic disease of the fetus and newborn is a fetal or neonatal hemolytic condition referenced as an immune globulin indication.
    Alternate nameIt is also known as erythroblastosis fetalis.
    Policy statusThe indication was added to the policy.
    IVIG/SQIG
    IVIGIVIG refers to intravenous immune globulin therapy.
    SQIGSQIG refers to subcutaneous immune globulin therapy.
    Policy contextBoth intravenous and subcutaneous administration routes are referenced in the policy.
    Severe refractory Myasthenia Gravis
    Revision actionThe policy revision history states that a definition for severe refractory Myasthenia Gravis was added.
    Definition textThe definition itself is not included in the available policy text window.
    Related classificationThe policy identifies severe refractory MG with MGFA Class IV in the clinical criteria.